Study identifies genetic marker which could personalize treatment for Crohn's...
The largest study ever to look at why an expensive and commonly used group of drugs fails some patients with Crohn's disease has identified a genetic marker which could individualize drug treatment.
View ArticleCrohn's disease study identifies genetic variant with potential to...
A genetic variant carried by 40 of the population explains why some patients develop antibodies against the antiTNF drugs infliximab and adalimumab and lose response. The authors conclude that a...
View ArticleIBD Patients Have High Exposure to Ionizing Radiation
Patients in Ontario with inflammatory bowel disease IBD and particularly those with Crohn's disease CD are at risk for high exposure to ionizing radiation from abdominal computed tomography CT scanning...
View ArticleEurecon Verlag Gmbh 20th Pharma Trend Image & Innovation Awards These Are the...
Bayer Vital with its subsidiary Jenapharm is the Best Pharmaceutical Company in the 2019 Pharma Trend Ranking. Novartis Pharma and Roche Pharma take second and third place respectively followed by...
View ArticleGali Health Launches Intelligent Personal Health Assistant
Gali Mobile Application for People With IBD Now Available in Apple App StoreGali Health a health technology company working to advance personalized medicine across chronic disease verticals today...
View ArticleGilead and Galapagos Announce Efficacy and Safety Results of Filgotinib...
Gilead Sciences Inc. NASDAQ GILD and Galapagos NV Euronext & NASDAQ GLPG today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib an...
View ArticleResearchers Find Dietary Changes That Help Treat Inflammatory Bowel Disease
Credit Rimma BondarenkoShutterstockIn recent years researchers have pinpointed a group of compounds called FODMAPs that are common trigger foods for people with irritable bowel syndrome. But it wasnt...
View ArticleResearchers Find Dietary Changes That Help Treat Irritable Bowel Disease
Credit Rimma BondarenkoShutterstockIn recent years researchers have pinpointed a group of compounds called FODMAPs that are common trigger foods for people with irritable bowel syndrome. But it wasnt...
View ArticleRedHill Biopharma Announces Full Results from Phase 3 Study and Supportive...
TELAVIV Israel and RALEIGH N.C. Oct. 11 2019 GLOBE NEWSWIRE &8212;ÂRedHill Biopharma Ltd.ÂNasdaqÂRDHL TelAviv Stock ExchangeÂRDHL RedHill or the Company a specialty biopharmaceutical company...
View ArticleHuman medicines European public assessment report EPAR Remicade infliximab...
Human medicines European public assessment report EPAR Remicade infliximab Spondylitis AnkylosingArthritis RheumatoidPsoriasisCrohn DiseaseArthritis PsoriaticColitis Ulcerative Date of authorisation...
View ArticleNeuClone Announces First Human Dose of Stelara Ustekinumab Biosimilar...
NeuClone a clinicalstage biopharmaceutical company exclusively focused on developing highquality biosimilar products today announced it has commenced dosing of Stelara ustekinumab biosimilar candidate...
View ArticleDevelopment of AntiDrug Antibodies to Infliximab Remicade and Adalimumab...
1. Carriage of the HLADQA105 allele is significantly associated with the development of antibodies against antiTNF agents. Evidence Rating Level 2 Good Antitumor necrosis factor antiTNF therapies are...
View ArticleStudy Suggests Adalimumab Exposure in Pregnancy Does Not Increase Birth...
602 Pregnancies Examined by the NonProfit Organization of Teratology Information SpecialistsLA JOLLA Calif. PRWEB October 18 2019 A new study conducted by birth defects experts from the Organization of...
View ArticleArena Pharmaceuticals Inc ARNA Financial and Strategic SWOT Analysis Review...
Arena Pharmaceuticals Inc ARNA Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by...
View ArticleNew subcutaneous formulation of Celltrion Healthcares CTP13 biosimilar...
Results from a multicentre openlabel randomised Phase 1 pivotal study showed that the subcutaneous SC formulation of CTP13 biosimilar infliximab was noninferior to intravenous IV formulation of CTP13...
View ArticleGenentechs Tecentriq in Combination With Avastin Increased Overall Survival...
First Phase III cancer immunotherapy study to show an improvement in overall survival and progressionfree survival for the treatment of the most common form of liver cancer Data will be submitted to...
View ArticleRetrospective RealWorld Comparative Analysis Highlights Safety of Vedolizumab...
Latest realworld data presented at UEG Week 2019 complements the extensive body of clinical evidence for the gutselective biologic vedolizumab in biologicnave patients with moderately to severely...
View ArticleSTELARAÂ ustekinumab Data Demonstrate Longterm Efficacy and Safety Results in...
Twoyear UNIFI data presented for the first time as a late breaking oral presentation at United European Gastroenterology Week UEGW congressThe Janssen Pharmaceutical Companies of Johnson &...
View ArticlePredictImmune Announces New Strategic Partnership to Commercialise its...
Exclusive deal with KSL Biomedical signals PredictImmunes major move into North AmericaPredictImmune developers of pioneering prognostic tools for guiding treatment options and improving patient...
View ArticleProvention Bios Phase 2a Trial of its Oral CSF1R Inhibitor Fails to Meet...
OLDWICK N.J. Oct. 22 2019 PRNewswire &8212; Provention Bio Inc. Nasdaq PRVB a clinical stage biopharmaceutical company dedicated to intercepting and preventing immunemediated disease today...
View Article